

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : National Stage Entry of PCT/EP2004/000134  
Applicant : Gudrun Rappold-Hoerbrand et al  
Filed : July 1, 2005  
TC/A.U. :  
Examiner :

Docket No. : 2951-140  
Customer No. : 6449  
Confirmation No.:

**INFORMATION DISCLOSURE STATEMENT**

Director of the United States Patent  
and Trademark Office  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report and are provided herewith for Examiner's review.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 02-2135.

Respectfully submitted,

By



Robert B. Murray  
Attorney for Applicants  
Registration No. 22,980  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 800, 1425 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202)783-6040

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	New Application <b>10/541388</b>
				Filing Date	July 1, 2005
				First Named Inventor	Rappold-Hoerbrand et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2951-140

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	1.	WO	01/34181	A	Rao, Rappold-Hoerbrand	5/17/2001	
	2.	EP	1 260 228	A	Rappold-Hoerbrand	11/27/02	
	3.	WO	02 074234	A	Prochon Biotech Inc.	9/26/02	
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	New Application <b>10/541388</b>
				Filing Date	July 1, 2005
				First Named Inventor	Rappold-Hoerbrand et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	2951-140

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	4.	Rao et al., "The Leri-Weill syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator", HUMAN MOLECULAR GENETICS, vol. 10, no. 26, 2001, pgs. 3083-3091.	
	5.	DATABASE MEDLINE US National Library of Medicine (NLM), Bethesda, MD, Abstract No. NLM1070532 2002, Bettencourt P., "Bain natriuretic peptide (nesiritide) in the treatment of heart failure".	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.